An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease

Gastroenterology

Volumn 117, Issue 6, 1999, Pages 1278-1287

  Vasiliauskas, E A ^a   Kam, L Y ^a   Abreu Martin, M T ^a   Hassard, P V ^a   Papadakis, K A ^a   Yang, H ^a   Zeldis, J B ^a   Targan, S R ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; STEROID; THALIDOMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CROHN DISEASE; DERMATITIS; DISEASE ACTIVITY; DRUG INDUCED DISEASE; EDEMA; HUMAN; MALE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; STEROID THERAPY; TREATMENT OUTCOME;

EID: 0032714405     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(99)70277-5     Document Type: Article

References (42)

1. T Andus SR Targan Glucocorticoids S Targan F Shanahan Inflammatory bowel disease: from bench to bedside 1993 Williams & Wilkins Baltimore, MD 487 502
2. SB. Hanauer Inflammatory bowel disease N Engl J Med 334 1996 841 848
3. WJ. Sandborn A critical review of cyclosporine therapy in inflammatory bowel disease Inflamm Bowel Dis 1 1995 48 63
4. MT Abreu-Martin EA Vasiliauskas J Gaiennie B Voigt SR. Targan Continuous infusion cyclosporine (CSA) is effective for severe acute Crohn's disease (CD). . .but for how long (abstr) Gastroenterology 110 1996 A851
5. SJH. Van Deventer Tumor necrosis factor and Crohn's disease Gut 40 1997 443 448
6. EJ Breese CA Michie SW Nicholls SH Murch CB Williams P Domizio JA Walker-Smith TT MacDonald Tumor necrosis factor α–producing cells in the intestinal mucosa of children with inflammatory bowel disease Gastroenterology 106 1994 1455 1466
7. TT MacDonald P Hutchings MY Choy S Murch A. Cooke Tumor necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and inflamed human intestine Clin Exp Immunol 81 1990 301 305
8. SH Murch CP Braegger JA Walker-Smith TT MacDonald Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease Gut 34 1993 1705 1709
9. HM van Dullemen SJH van Deventer DW Hommes HA Bijl J Jansen GNJ Tytgat J Woody Treatment of Crohn's disease with anti–tumor necrosis factor chimeric monoclonal antibody (cA2) Gastroenterology 109 1995 129 135
10. SR Targan SB Hanauer SJH van Deventer L Mayer DH Present T Braakman KL DeWoody TF Schaible PJ Rutgeerts A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease N Engl J Med 337 1997 1029 1035
11. WA Stack SD Mann AJ Roy P Heath M Sopwith J Freeman G Holmes R Long A Forbes MA Kamm CJ Hawkey Randomised controlled trial of CDP57l antibody to tumour necrosis factor–α in Crohn's disease Lancet 349 1997 521 524
12. DH Present P Rutgeerts S Targan SB Hanauer L Mayer RA van Hogezand DK Podolsky BE Sands T Braakman KL DeWoody TF Schaible SJH. van Deventer Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1999 1398 1405
13. MJ Elliott RN Maini M Feldmann A Long-Fox P Charles H Bijl JN. Woody Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis Lancet 344 1994 1125 1127
14. WJ Sandborn SB. Hanauer Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety Inflamm Bowel Dis 5 1999 119 133
15. SB Hanauer PJ Rutgeerts G D'Haens SR Targan L Kam DH Present L Mayer C Wagner J LaSorda B Sands RA Livingston Delayed hypersensitivity to infliximab (Remicadet®) re-infusion after a 2-4 year interval without treatment (abstr) Gastroenterology 116 1999 A731
16. CG Iyer J Languillon K Ramanujam G Tarabini-Castellani JT De las Aguas LM Bechelli K Uemura V Martinez Dominguez T. Sundaresan WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients Bull World Health Organ 45 1971 719 732
17. MF. Waters An internally-controlled double blind trial of thalidomide in severe erythema nodosum leprosum Lepr Rev 42 1971 26 42
18. WHO Expert Committee on Leprosy Sixth Report 1988 World Health Organization Geneva, Switzerland Technical Report Series 768
19. O Gutiérrez-Rodríguez P Starusta-Bacal O Gutiérrez-Montes Treatment of refractory rheumatoid arthritis—the thalidomide experience J Rheumatol 16 1989 158 163
20. H Larsson Treatment of severe colitis in Behçet's syndrome with thalidomide (CG-217) J Intern Med 228 1990 405 407
21. V Hamuryudan C Mat S Saip Y Özyazgan A Siva S Yurdakul K Zwingenberger H Yazici Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial Ann Intern Med 128 1998 443 450
22. AL Moreira EP Sampaio A Zmuidzinas P Frindt KA Smith G Kaplan Thalidomide exerts its inhibitory action on TNF-α by enhancing mRNA degradation J Exp Med 177 1993 1675 1680
23. DR Moller M Wysocka BM Greenlee X Ma L Wahl DA Flockhart G Trinchieri CL. Karp Inhibition of IL-12 production by thalidomide J Immunol 159 1997 5157 5161
24. MF Neurath I Fuss B Kelsall KH Meyer zum Buschenfelde W. Strober Effect of IL-12 and antibodies to IL-12 on established granulomatous colitis in mice Ann NY Acad Sci 795 1996 368 370
25. AR Wettstein AP. Meagher Thalidomide in Crohn's disease Lancet 350 1997 1445 1446
26. EB Odeka V. Miller Thalidomide in oral Crohn's disease refractory to conventional medical treatment J Pediatr Gastroenterol Nutr 25 1997 250 251
27. TA Weinstein JJ Sciubba J. Levine Thalidomide for the treatment of oral aphthous ulcers in Crohn's disease J Pediatr Gastroenterol Nutr 28 1999 214 216
28. S Tseng G Pak K Washenik MK Pomeranz JL. Shupack Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses J Am Acad of Dermatol 35 1996 969 979
29. GB Vogelsang ER Farmer AD Hess V Altamonte WE Beschorner DA Jabs RL Corio LS Levin OM Colvin JR Wingard GW. Santos Thalidomide for the treatment of chronic graft-versus-host disease N Engl J Med 326 1992 1055 1058
30. PM Parker N Chao A Nademanee MR O'Donnell GM Schmidt DS Snyder AS Stein EP Smith A Molina DE Stepan A Kashyap I Planas R Spielberger G Somlo K Margolin K Zwingenberger K Wilsman RS Negrin GD Long JC Niland KG Blume SJ. Forman Thalidomide as salvage therapy for chronic graft-versus-host disease Blood 86 1995 3604 3609
31. PM Fullerton DJ. O'Sullivan Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study J Neurol Neurosurg Psychiatry 31 1968 543 551
32. CH Wulff H Hoyer G Asboe-Hansen H. Brodthagen Development of polyneuropathy during thalidomide therapy Br J Dermatol 112 1985 475 480
33. V Chaudhry D Cornblath A Corse M Freimer E Simmons-O'Brien G Vogelsang Thalidomide–induced neuropathy: clinical and eletrophysiological features Neurology 46 1996 A283
34. WR Best JM Becktel JW. Singleton Rederived values of the eight co-efficients of the Crohn's Disease Activity Index (CDAI) Gastro-enterology 77 1979 843 846
35. GW Mellin M. Katzenstein The saga of thalidomide (concluded): neuropathy to embryopathy, with case reports of congenital anomalies N Engl J Med 24 1962 1238 1244
36. JM Manson LD. Wise Teratogens MO Amdur J Doull CD Klaassen Casarett and Doull's toxicology: the basic science of poisons. 1991 Pergamon New York 226 254
37. Thalomid (thalodomide) 1999 Prescribing information. Physicians Desk Reference
38. EJ Irvine B Feagan J Rochon A Archambault RN Fedorak A Groll D Kinnear F Saibil JW. McDonald Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease Gastroenterology 106 1994 287 296
39. SV Kane ED Ehrenpreis LB Cohen SB Hanauer RD. Cohen Therapeutic efficacy of thalidomide for patients with refractory Crohn's disease (CD) (abstr) Gastroenterology 116 1999 A745
40. V Günzler Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations Drug Saf 7 1992 116 134
41. A Lagueny A Rommel B Vignolly A Taieb M Vendeaud-Busquet MS Doutre J. Julien Thalidomide neuropathy: an electrophysiologic study Muscle Nerve 9 1986 837 844
42. I Williams IVD Weller A Malni J Anderson MFR. Waters Thalidomide hypersensitivity in AIDS Lancet 337 1991 436 437